diphtheria + acellular pertussis + tetanus

The combination of diphtheria toxoid, tetanus toxoid, and acellular pertussis antigens is an inactivated toxoid/subunit vaccine used for active immunization against diphtheria, tetanus, and pertussis (whooping cough) across pediatric, adolescent, and adult populations.[1][4][7][8][9] The diphtheria and tetanus components consist of formaldehyde-inactivated toxins (toxoids) from Corynebacterium diphtheriae and Clostridium tetani, adsorbed to aluminum salts to enhance immunogenicity, while the acellular pertussis component contains purified inactivated Bordetella pertussis antigens such as pertussis toxin, filamentous hemagglutinin, pertactin, and fimbriae, which elicit protective antibody responses without whole-cell reactogenicity.[1][4][7] Pediatric formulations (DTaP) with higher diphtheria and pertussis antigen content are used as a 5-dose primary and booster series in children 6 weeks through 6 years, while reduced-antigen formulations (Tdap) are used as booster doses in older children, adolescents, adults, and during pregnancy to protect newborns.[1][4][7][8][9] Multiple manufacturers (notably Sanofi and GSK) supply licensed DTaP and Tdap products globally, and these vaccines are core components of routine immunization schedules due to their high effectiveness against tetanus and diphtheria and good, though waning, protection against pertussis.[1][4][7][8][9]

Other names

diphtheria and tetanus toxoids and acellular pertussis vaccinediphtheria-tetanus-acellular pertussis vaccineDTaPtetanus-diphtheria-acellular pertussis vaccineTdap